TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03413163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ultrasound guided erector spinae plane block
Description: A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to T9 spinous process. The erector spinae muscles will be identified superficial to the tip of T9 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.375% bupivacaine will be injected (maximum of 3mg/kg).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Pain Followup and Monitorization
Description: Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Pain Followup and Monitorization
Description: Numeric Rating Scale (NRS) pain score will be recorded from 20th minute in recovery room followed by 1.-3.-6.-12.-18.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 6 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 6 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 6 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
Study: NCT03446976

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P13 SC Auto-injector
Description: Each subject may receive single dose by subcutaneous administration using Auto-Injector

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CT-P13 SC Pre-filled Syringe
Description: Each subject may receive single dose by subcutaneous administration using Pre-filled Syringe
Study: NCT03373760

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Given IV
Study: NCT01093586

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: double-unit umbilical cord blood transplantation
Description: Undergo transplantation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cytogenetic analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone marrow aspiration
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fluorescence in situ hybridization
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given orally or IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo transplantation
Study: NCT00105989

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT01773603

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Embryoscope
Description: Five-day embryo culture in embryoscope which is an incubator with a built-in camera
Study: NCT00357877

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10% w/v chlorhexidine acetate coating FDA IND #45466
Description: Dental coating topically applied by dental professional supragingivally to the full dentition

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01051557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perifosine
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo cytoreductive surgery
Study: NCT01863290

Intervention type: OTHER
Intervention: Primary care redesign
Description: Connect individuals released from prison to primary care using trained, culturally competent primary care providers and community health workers (CHWs).
Study: NCT00534872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB-649868
Description: 10 mg
Study: NCT02950116

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Perform three multiple breath nitrogen washout tests (N2-MBW-test)
Description: * Patient is sitting in upright position, nose clip in place and breathing through a mouth piece with filter (neither sitting forward with back bent, nor supporting arms such that shoulders are raised)~* Patient's breathing pattern is stable for a minimum of 5 breaths~* Start of washout by inhaling 100% oxygen (initiated by lab technician)~* Continuous stable breathing pattern until end of washout test~* End target = 1/40th of start N2 concentration~* To ensure end of washout is achieved, patients should breathe 5 more breaths below the target concentration before the trial is terminated~* Three N2-MBW-tests are performed consecutively. Time between each test is \[duration of the previous test\*1.5\] (e.g. test duration = 6 min., time to next test = 6\*1.5 = 9 min.)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Perform three multiple breath nitrogen washout tests (N2-MBW-test)
Description: * Patient is sitting in upright position, nose clip in place and breathing through a mouth piece with filter (neither sitting forward with back bent, nor supporting arms such that shoulders are raised)~* Patient's breathing pattern is stable for a minimum of 5 breaths~* Start of washout by inhaling 100% oxygen (initiated by lab technician)~* Continuous stable breathing pattern until end of washout test~* End target = 1/40th of start N2 concentration~* To ensure end of washout is achieved, patients should breathe 5 more breaths below the target concentration before the trial is terminated~* Three N2-MBW-tests are performed consecutively. Time between each test is \[duration of the previous test\*1.5\] (e.g. test duration = 6 min., time to next test = 6\*1.5 = 9 min.)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Perform three multiple breath nitrogen washout tests (N2-MBW-test)
Description: * Patient is sitting in upright position, nose clip in place and breathing through a mouth piece with filter (neither sitting forward with back bent, nor supporting arms such that shoulders are raised)~* Patient's breathing pattern is stable for a minimum of 5 breaths~* Start of washout by inhaling 100% oxygen (initiated by lab technician)~* Continuous stable breathing pattern until end of washout test~* End target = 1/40th of start N2 concentration~* To ensure end of washout is achieved, patients should breathe 5 more breaths below the target concentration before the trial is terminated~* Three N2-MBW-tests are performed consecutively. Time between each test is \[duration of the previous test\*1.5\] (e.g. test duration = 6 min., time to next test = 6\*1.5 = 9 min.)
Study: NCT02959216

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Participants will be given a prescription to exercise up to 90% of their threshold heart rate for symptom exacerbation. Heart rate threshold will be monitored weekly in order to increase exercise level accordingly.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Stretching Exercise
Description: Participants will be given a prescription to complete a standardized stretching protocol.
Study: NCT02988739

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: seasonal influenza vaccine
Description: influenza vaccine containing 15 µg haemagglutinin of three seasonal influenza virus strains recommended by WHO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: seasonal influenza vaccine
Description: influenza vaccine containing 15 µg haemagglutinin of three seasonal influenza virus strains recommended by WHO

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractional Er:Yag laser
Description: Fraction laser device to apply micorpores of defined depth and density into skin.
Study: NCT01869777

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bioelectric impedance analysis
Description: Undergo bioelectric impedance analysis
Study: NCT03866421

Intervention type: DIAGNOSTIC_TEST
Intervention: MR spectroscopy of the liver
Description: Magnetic resonance spectroscopy of the liver. Golden standard for non-invasive determination of NAFLD

Intervention type: DIAGNOSTIC_TEST
Intervention: MR spectroscopy of the liver
Description: Magnetic resonance spectroscopy of the liver. Golden standard for non-invasive determination of NAFLD

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroscan of the liver
Description: Transient Elastography for Measurement of liver fibrosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fibroscan of the liver
Description: Transient Elastography for Measurement of liver fibrosis.

Intervention type: DEVICE
Intervention: Continuous glucose monitoring (CGM) for four days.
Description: CGM is attached to the abdominal skin for four days. Afterwards data is converted and analysed in a computer program.

Intervention type: DEVICE
Intervention: Continuous glucose monitoring (CGM) for four days.
Description: CGM is attached to the abdominal skin for four days. Afterwards data is converted and analysed in a computer program.

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test (OGTT)
Description: OGTT with incretin hormones. Measured for three hours.

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral glucose tolerance test (OGTT)
Description: OGTT with incretin hormones. Measured for three hours.

Intervention type: DIAGNOSTIC_TEST
Intervention: Intra venous glucose infusion (IIGI)
Description: This test is combined with the OGTT to compare responses of parenteral vs enteral stimulation. The test is followed by a bolus of 5 g of L-arginin.

Intervention type: DIAGNOSTIC_TEST
Intervention: Intra venous glucose infusion (IIGI)
Description: This test is combined with the OGTT to compare responses of parenteral vs enteral stimulation. The test is followed by a bolus of 5 g of L-arginin.

Intervention type: RADIATION
Intervention: Dual Energy X-ray Absorptiometry (DEXA) scan
Description: DEXA-scan of the body composition.

Intervention type: RADIATION
Intervention: Dual Energy X-ray Absorptiometry (DEXA) scan
Description: DEXA-scan of the body composition.

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Immediately analyse of basic lab data. Later analyses for glucagon, amino acids, bile acids, lipidomics and metabolomics.

Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Immediately analyse of basic lab data. Later analyses for glucagon, amino acids, bile acids, lipidomics and metabolomics.

Intervention type: OTHER
Intervention: Clinical and demographic data
Description: Measurements of blood pressure, pulse, height, weight.

Intervention type: OTHER
Intervention: Clinical and demographic data
Description: Measurements of blood pressure, pulse, height, weight.
Study: NCT04199377

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIP KNEE REPLACEMENT
Description: HIP KNEE REPLACEMENT
Study: NCT00330694

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ParkNet
Description: Development of a network of dedicated physiotherapist with specific expertise in Parkinson's Disease and structured referrals to these ParkNet therapists by neurologists.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: No altered organisation of physiotherapy care in Parkinson's Disease
Study: NCT03591601

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy protocol
Description: Treatment based on manual therapy with proven evidence.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foam Rolling protocol
Description: Treatment based on massage with a Foam Rolling

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Placebo treatment based on the placement of the hands on the head without intention to treat.
Study: NCT03000985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: 6 session psychoeducation program with the family caregiver of schizophrenics patients.
Study: NCT02169505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Starting dose: 1.2 mg/kg by vein on Day 1 for the first 2, 21 day cycles. Dose increased to 1.8 mg/kg by vein after the second cycle for all subsequent cycles.
Study: NCT00613366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Place 2 tablets between the teeth and cheek and allow to dissolve for 30 minutes.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium Oxide
Description: Place 2 tablets between the teeth and cheek and allow to dissolve for 30 minutes.
Study: NCT00130689

Intervention type: DRUG
Group type: OTHER
Intervention: Cetuximab
Study: NCT02235181

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arabin Cervical Pessary
Description: The Arabin pessary is CE-certified for preventing Spontaneous Preterm Birth (SPB) (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC) and is being used in this study as per the CE certification and manufacturer's guidance.
Study: NCT03583879

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exoskeleton exercise
Description: Functional exercise with a robotic exoskeleton

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard exercise
Description: Functional exercise without a robotic exoskeleton

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No treatment
Description: Wait-list control
Study: NCT06371690

Intervention type: OTHER
Intervention: Web-Based Double-Eye Control Program
Description: Web-Based Double-Eye Control Program, a web-based drug dose calculation program, is compatible with smartphones, tablets and computers. On the interface of the website, the nurse is required to enter data such as the age, weight, medications and doses ordered by the physician of the patient. When all these data are entered, the amount of medication that the nurse should give and whether the ordered dose is within the safe dose range for the patient are calculated by the program, so that the nurse can control her own calculations. On the other interface of the website, there are medication instructions uploaded by the researchers. With this interface, nurses access all pharmacological information about especially high-risk drugs (indications, contraindications, interacting drugs and fluids, fluids to be used for diluting, medication route, medication pace, etc.) and information that will enable the medication to be carried out in a standard way.
Study: NCT04563754

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mHRME (Mobile High resolution microendoscope)
Description: Standard of care (SOC) high-resolution anoscopy (HRA) with Lugol's iodine will be performed. The unstained (abnormal) area will be evaluated with mHRME for optical biopsy diagnosis:~1. contrast agent will be applied to anal epithelium (5-10 ml of proflavine hemisulfate (0.01%)),~2. the mHRME will then be inserted and imaging of abnormal tissues will be performed. This will add 2 to 6 minutes per procedure.~This is a single-arm study where all subjects will receive both SOC HRA and experimental mHRME imaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proflavine Hemisulfate
Description: Contrast agent will be applied to anal epithelium (5-10 ml of proflavine hemisulfate (0.01%)) to use with the mHRME

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High resolution anoscopy
Description: Standard of care (SOC) HRA with Lugol's iodine will be performed.
Study: NCT03042351

Intervention type: DEVICE
Group type: OTHER
Intervention: Magic Kegel app
Description: Pelvic floor muscles recover exercises with a specific device and Magic Kegel App
Study: NCT01865721

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entonox
Description: Entonox will be used according to the allocated method

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entonox
Description: Entonox will be used according to the allocated method
Study: NCT03444805

Intervention type: PROCEDURE
Intervention: Autologous HSCT
Description: 1st AHSCT
Study: NCT02035553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin tartrate
Description: Pimavanserin tartrate, 40 mg (two 20 mg tablets), once daily by mouth (equivalent to 34 mg free base pimavanserin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, two tablets, once daily by mouth
Study: NCT01678118

Intervention type: BEHAVIORAL
Intervention: Patient Navigator
Description: The pt navigator will phone (email, text, or other preferred method of contact) pts prior to the date of previously set individual goals (e.g. going to an appt, getting their cessation medications filled, etc) as a reminder \& to discuss barriers such as finances, transportation or ambivalent motivation. In this manner, pts receive navigation services tailored to their individual needs \& barriers. Once pts are connected with a cessation service (defined as either using cessation medication or at least 1 contact with a Quitline or community-based cessation counselor)or provider-prescribed cessation medication usage, continues the navigation intervention will be considered complete. W/I the 3 month engagement period, pts will receive up to 6 contacts from the Pt Navigator following referral from primary care provider. Consistent with recommended pt navigation practice, the navigator will provide feedback to primary care provider regarding cessation services that the pts are receiving.
Study: NCT03868839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan Pill
Description: telmisartan 40mg once a day during week 1; the dose will be increased to 80mg (target dose) or as tolerated during the remaining three weeks.
Study: NCT04227418

Intervention type: DEVICE
Intervention: 12 lead ECG monitoring
Description: Rate, Rhythm, QTc and PR interval will be assessed

Intervention type: DEVICE
Intervention: 12 lead ECG monitoring
Description: Rate, Rhythm, QTc and PR interval will be assessed

Intervention type: DEVICE
Intervention: 6 lead ECG monitoring
Description: Rate, Rhythm, QTc and PR interval will be assessed

Intervention type: DEVICE
Intervention: 6 lead ECG monitoring
Description: Rate, Rhythm, QTc and PR interval will be assessed

Intervention type: DEVICE
Intervention: Hand held ECG monitoring
Description: Handheld ECG machines are portable, inexpensive, hand held devices that provide a 'real-time' rhythm strip, equivalent to lead I or II on a 12 lead machine, depending on how the device is held. The rhythm strip is displayed on a computer tablet or mobile phone, and are compatible with both android and iPhone platforms. To perform the test the patient places their fingers/thigh, or alternatively the device can be placed directly on the patient's chest. The process does not require the patient to be exposed, can be done in a seated position (negating the need an examination couch) and their ease of use and portability means they could be readily used in memory clinics or community settings.

Intervention type: DEVICE
Intervention: Hand held ECG monitoring
Description: Handheld ECG machines are portable, inexpensive, hand held devices that provide a 'real-time' rhythm strip, equivalent to lead I or II on a 12 lead machine, depending on how the device is held. The rhythm strip is displayed on a computer tablet or mobile phone, and are compatible with both android and iPhone platforms. To perform the test the patient places their fingers/thigh, or alternatively the device can be placed directly on the patient's chest. The process does not require the patient to be exposed, can be done in a seated position (negating the need an examination couch) and their ease of use and portability means they could be readily used in memory clinics or community settings.
Study: NCT01178125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-102
Study: NCT03795337

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiosurgery
Description: Image-guided stereotactic Linac based RT preferable with dedicated radiosurgery system such as CyberKnife
Study: NCT00094679

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye patch
Description: adhesive patch to cover the sound eye

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye patch
Description: adhesive patch to cover the sound eye
Study: NCT01674465

Intervention type: BIOLOGICAL
Intervention: Hypoxyprobe-1
Description: Hypoxyprobe-1 is a biological marker used to detect oxygen levels in tissue;subjects will receive and intravenous solution for 20 minutes containing 500mg/m\^2 two-three hours prior to their standard of care biopsy
Study: NCT03677115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: combination of ropivacaine and dexmedetomidine 20 ug every time
Study: NCT01711983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE® CARDIOFORM Septal Occluder
Description: Percutaneous Atrial Septal Defect Closure
Study: NCT04820322

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fibersym
Description: RS4-type resistant modified wheat starch

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control cookie
Description: control cookie